The White House is preparing to end Marty Makary’s tenure as Commissioner of the U.S. Food and Drug Administration (FDA). This decision follows internal discussions and has been formally approved, signaling a notable leadership change at the federal health agency.
In a significant development, Kyle Diamantas, the current FDA Deputy Commissioner responsible for the agency’s food division, is expected to be named acting commissioner. This move aims to maintain continuity during the transition period.
Makary, a well-known figure in the medical field, has guided the FDA through a challenging phase marked by intense regulatory scrutiny. However, the administration appears to be seeking a new direction to align the agency’s priorities more closely with its public health objectives.
While the exact reasons behind Makary’s removal have not been disclosed, such a departure often reflects a desire for a shift in policy approach or a realignment with executive goals. The decision is part of a broader reshuffle within the Department of Health and Human Services, indicating a strategic pivot in federal health oversight.
Diamantas, recognized for his expertise in food safety and nutrition policy, is considered a reliable choice to lead the agency temporarily. His extensive knowledge of the FDA’s internal operations positions him well to manage ongoing responsibilities, including drug approvals and food safety inspections, until a permanent commissioner is appointed.
